Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) saw strong trading volume on Friday . 633,416 shares were traded during mid-day trading, an increase of 56% from the previous session’s volume of 405,334 shares.The stock last traded at $7.52 and had previously closed at $7.34.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Aratana Therapeutics in a report on Sunday, July 17th. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Credit Suisse Group AG reiterated a “buy” rating on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Finally, Jefferies Group reiterated a “buy” rating and issued a $12.00 price target on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $11.66.

The firm’s market capitalization is $268.28 million. The stock’s 50-day moving average is $6.55 and its 200 day moving average is $5.40.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. Equities research analysts forecast that Aratana Therapeutics Inc. will post ($1.02) EPS for the current fiscal year.

In other news, insider Ernst Heinen sold 15,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $6.72, for a total transaction of $100,800.00. Following the sale, the insider now directly owns 125,494 shares of the company’s stock, valued at approximately $843,319.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Julia A. Stephanus sold 30,000 shares of the stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total transaction of $187,500.00. Following the sale, the insider now directly owns 127,503 shares in the company, valued at $796,893.75. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates boosted its stake in Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned approximately 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent filing with the SEC.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.